Key terms
About BYSI
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. The Plinabulin Pipeline segment focuses on the development of cancer therapies. The TPD Platform segment engages in the development of therapeutic agents and discover chemical entities. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BYSI news
Mar 25
7:15am ET
BeyondSpring reports first patient dosed with pembrolizumab, plinabulin plus EP
Mar 18
9:57am ET
BeyondSpring Announces Executive Leadership Change
Feb 26
8:14am ET
BeyondSpring regains compliance with Nasdaq minimum bid price rule
Jan 10
3:02pm ET
BeyondSpring reports Nasdaq delinquency notice for late filing
No recent press releases are available for BYSI
BYSI Financials
Key terms
Ad Feedback
BYSI Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BYSI Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
